Semaglutide
Wegovy
Sources
fda, as of 2026-05-05Stale
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/215256Orig1s031.pdf
Sponsor: Novo Nordisk Inc. Trade Name: WEGOVY. Generic or Proper Name: semaglutide. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. WEGOVY injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity. WEGOVY tablets are indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity.
Approval package 215256Orig1s031, highlights and Table 8 Study 2 and Table 12 Study 8
registry, as of 2021-11-19Stale
https://clinicaltrials.gov/study/NCT03548935
Protocol section, NCT03548935, last update posted 2021-11-19
registry, as of 2026-04-23Stale
https://clinicaltrials.gov/study/NCT05646706
Protocol section, NCT05646706 STEP UP, last update posted 2026-04-23
registry, as of 2024-08-30Stale
https://clinicaltrials.gov/study/NCT03574597
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 17604. Conditions Overweight; Obesity. The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Change in Body Weight Semaglutide -9.39 percentage change in body weight Week 0, week 104 Change in Body Weight Placebo -0.87 percentage change in body weight Week 0, week 104 Change in HbA1c - Percentage Semaglutide -0.31 Percentage of HbA1c Change in HbA1c - Percentage Placebo 0.01 Percentage of HbA1c Change in HbA1c - mmol/Mol Semaglutide -3.38 mmol/mol Change in HbA1c - mmol/Mol Placebo 0.1 mmol/mol de
ClinicalTrials.gov NCT03574597 protocol and results modules
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07866066
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 1300. Conditions Diabetes Mellitus, Type 2. The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2)
ClinicalTrials.gov NCT07866066 protocol and results modules
registry, as of 2026-10-06Stale
https://clinicaltrials.gov/study/NCT07284979
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Kailera. Enrollment 1270. Conditions Obesity. The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
ClinicalTrials.gov NCT07284979 protocol and results modules
registry, as of 2021-11-09Stale
https://clinicaltrials.gov/study/NCT03552757
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 1210. Conditions Obesity; Overweight. This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the Change in Body Weight (%) - Semaglutide 2.4 mg Versus Semaglutide 1.0 mg Semaglutide 2.4 mg -9.9 Percentage point of body weight Baseline (week 0) to week 68 Change in Body Weight (%) - Semaglutide 2.4 mg Versus Semaglutide 1.0 mg Semaglutide 1.0 mg -7.2 Percentage point of body weight Baseline (week 0) to week 68 Change in HbA1c (%) Semaglutide 1.0 mg -1.5 Percentage po
ClinicalTrials.gov NCT03552757 protocol and results modules
registry, as of 2026-03-12Stale
https://clinicaltrials.gov/study/NCT07400107
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 1000. Conditions Obesity; Overweight; Diabetes Mellitus, Type 2. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin
ClinicalTrials.gov NCT07400107 protocol and results modules
registry, as of 2022-01-19Stale
https://clinicaltrials.gov/study/NCT03548987
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 902. Conditions Metabolism and Nutrition Disorder; Obesity. This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, the participa Change From Randomisation to Week 68 in Body Weight (%) In-trial Semaglutide 2.4 mg -8.3 Percentage point Randomisation (week 20) to week 68 Change From Randomisation to Week 68 in Body Weight (%) In-trial Placebo 6.5 Percentage point Randomisation (week 20) to week 68 Change From Randomisation to Week 68 in Body Weight (%) On-treatment Semaglutide 2.4 mg -8.8 Percentag
ClinicalTrials.gov NCT03548987 protocol and results modules
registry, as of 2025-11-26Stale
https://clinicaltrials.gov/study/NCT05822830
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 751. Conditions Obesity; Overweight. The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks. Percentage of Participants Who Achieve ≥10% Body Weight Reduction 15 mg or MTD - Tirzepatide 87.7 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 2.4 mg or MTD - Semaglutide 66.7 Percentage of Participants Who Achieve ≥15% Body Weight Reduction 15 mg or MTD - Tirzepatide 71.7 Percentage of Participants Who Achieve ≥15% Body Weight Reduction 2.4 mg or MTD - Semaglutide 45.0
ClinicalTrials.gov NCT05822830 protocol and results modules
registry, as of 2026-09-28Stale
https://clinicaltrials.gov/study/NCT07668414
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 650. Conditions Overweight; Obesity. The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
ClinicalTrials.gov NCT07668414 protocol and results modules
registry, as of 2026-11-02
https://clinicaltrials.gov/study/NCT04916470
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 617. Conditions Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2. This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart Percentage Change in Body Weight Semaglutide 2.4 mg -10.2 Percentage change in body weight Baseline (week 0), end of treatment (week 52) Percentage Change in Body Weight Placebo -3.2 Percentage change in body weight Baseline (week 0), end of treatment (week 52) Change in Glycated Haemoglobin (HbA1c) Semaglutide 2.4
ClinicalTrials.gov NCT04916470 protocol and results modules
registry, as of 2021-11-11Stale
https://clinicaltrials.gov/study/NCT03611582
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 611. Conditions Overweight; Obesity. This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. Together with the medicine, the participant will Change in Body Weight (%) In-trial observation period Semaglutide 2.4 mg -16.5 Percentage Baseline (week 0) to week 68 Change in Body Weight (%) In-trial observation period Placebo -5.8 Percentage Baseline (week 0) to week 68 Change in Body Weight (%) On-treatment observation period Semaglutide 2.4 mg -17.6 Percentage Baseline (week 0) to week 68 Change in Body Weight (%)
ClinicalTrials.gov NCT03611582 protocol and results modules
registry, as of 2026-05-11Stale
https://clinicaltrials.gov/study/NCT05514535
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE). Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 573. Conditions Diabetes Mellitus, Type 2; Obesity. This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide toget Change in Glycated Haemoglobin (HbA1c) [Noninferiority] Insuline Glargine U100 (Reduced) + Semaglutide -1.37 Percentage point of HbA1c Change in Glycated Haemoglobin (HbA1c) [Noninferiority] Insuline Glargine U100 (Titrated) -0.65 Percentage point of HbA1c Change in Glycated Haemoglobi
ClinicalTrials.gov NCT05514535 protocol and results modules
registry, as of 2026-02-27Stale
https://clinicaltrials.gov/study/NCT07285902
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 572. Conditions Obesity. This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
ClinicalTrials.gov NCT07285902 protocol and results modules
registry, as of 2025-12-05Stale
https://clinicaltrials.gov/study/NCT04788511
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 529. Conditions Obesity. This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in peo Change in Body Weight Semaglutide 2.4 mg -13.9 Percentage of body weight From baseline (week 0) to end of treatment (week 52) Change in Body Weight Placebo -2.5 Percentage of body weight From baseline (week 0) to end of treatment (week 52) Percentage of Participants Achieving 10 Percent (%) Weight Loss (Yes/No) Semaglutide 2.4 mg 34.1 Percentage of Participants Achieving 10 Percent (%) Weight Loss (Yes
ClinicalTrials.gov NCT04788511 protocol and results modules
registry, as of 2026-04-27Stale
https://clinicaltrials.gov/study/NCT05649137
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 512. Conditions Obesity; Diabetes Mellitus, Type 2. This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people t Relative Change in Body Weight Semaglutide 7.2 mg -13.5 Percentage (%) change in body weight Baseline (week 0), End of treatment (week 72) Relative Change in Body Weight Semaglutide 2.4 mg -10.7 Percentage (%) change in body weight Baseline (week 0), End of treatment (week 72) Relative Change in Body Weight Placebo -4.0 Percentage (%) change in body weight Baseline (week 0), E
ClinicalTrials.gov NCT05649137 protocol and results modules
registry, as of 2024-09-27Stale
https://clinicaltrials.gov/study/NCT06616961
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Popular Medical College Hospital. Enrollment 480. Conditions Obesity; Type 2 Diabetes Mellitus (T2DM). The goal of this clinical trial is to learn if semaglutide can help with weight loss in overweight or obese adults in Bangladesh. The study will also look at how safe semaglutide is for these participants. The main questions to answers are given below: Does semaglutide help part
ClinicalTrials.gov NCT06616961 protocol and results modules
registry, as of 2026-04-06Stale
https://clinicaltrials.gov/study/NCT06604624
Semaglutide in Treatment of Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 462. Conditions Weight Management. This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.
ClinicalTrials.gov NCT06604624 protocol and results modules
registry, as of 2026-09-25Stale
https://clinicaltrials.gov/study/NCT06738979
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects. Overall status COMPLETED. Phases PHASE3. Lead sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Enrollment 408. Conditions Obesity. This is a multicenter, randomized, open, parallel, positive-controlled clinical study to evaluate the efficacy and safety of Semaglutide injection (TQF3510) developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in obese subjects (BMI≥28 kg/m2). Equivalence tests were per
ClinicalTrials.gov NCT06738979 protocol and results modules
registry, as of 2025-11-17Stale
https://clinicaltrials.gov/study/NCT05064735
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 407. Conditions Obesity. This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on Percentage Change in Body Weight Semaglutide 2.4 mg -14.2 Percentage change in body weight Baseline (week 0), end of treatment (week 68) Percentage Change in Body Weight Placebo -2.5 Percentage change in body weight Baseline (week 0), end of treatment (week 68) Percentage of Participants Achieving Body Weight Reduction Greater Than or Equal to (≥) 5 Percent (%) (Yes/No) Semaglutide 2.4 mg 87.0 Per
ClinicalTrials.gov NCT05064735 protocol and results modules
registry, as of 2022-03-22Stale
https://clinicaltrials.gov/study/NCT03811574
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 401. Conditions Overweight; Obesity. This study will look at the change in participants' body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, participants Change in Body Weight (%) Semaglutide 1.7 mg -9.9 Percentage change Baseline (week 0), week 68 Change in Body Weight (%) Semaglutide 2.4 mg -13.4 Percentage change Baseline (week 0), week 68 Change in Body Weight (%) Placebo -1.9 Percentage change Baseline (week 0), week 68 Change in HbA1c (%) Semaglutide 1.7 mg -0.9 Percentage of HbA1c Change in HbA1c (%) Semaglutide 2.4 mg -1.0 Percenta
ClinicalTrials.gov NCT03811574 protocol and results modules
registry, as of 2026-01-29Stale
https://clinicaltrials.gov/study/NCT04251156
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 375. Conditions Overweight; Obesity; Diabetes Mellitus, Type 2. This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine particip Change From Baseline in Body Weight (Percentage [%]) Semaglutide 2.4 mg -12.5 Percentage change Baseline (week 0), week 44 Change From Baseline in Body Weight (Percentage [%]) Placebo -3.6 Percentage change Baseline (week 0), week 44 Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%]) Semaglutide 2.4 mg -0.8 Percentage of HbA1c Change From Baseline in Glyco
ClinicalTrials.gov NCT04251156 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07743983
A Study of BGM0504 in Early T2DM With Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 372. Conditions Type 2 Diabetes (T2DM). This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, efficacy and safety are evaluated, including the
ClinicalTrials.gov NCT07743983 protocol and results modules
registry, as of 2024-10-09Stale
https://clinicaltrials.gov/study/NCT06633783
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Hangzhou Jiuyuan Gene Engineering Co. Ltd.,. Enrollment 370. Conditions Obesity. The purpose of the study is to compare the effect on body weight in subjects taking semaglutide injection or subjects taking Wegovy®.
ClinicalTrials.gov NCT06633783 protocol and results modules
registry, as of 2026-06-03Stale
https://clinicaltrials.gov/study/NCT07622810
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Carnot Laboratories. Enrollment 352. Conditions Obesity & Overweight. The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity. It will also evaluate the effects of treatment on metabolic parameters, cardiovascular risk factors, and q
ClinicalTrials.gov NCT07622810 protocol and results modules
registry, as of 2023-07-06Stale
https://clinicaltrials.gov/study/NCT03693430
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 304. Conditions Overweight; Obesity. This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talk Percentage Change From Baseline (Week 0) to Week 104 in Body Weight In-trial observation period Semaglutide 2.4 mg -15.9 percentage change From Baseline (Week 0) to Week 104 Percentage Change From Baseline (Week 0) to Week 104 in Body Weight In-trial observation period Placebo -1.9 percentage change From Baseline (Week 0) to Week 104 Percentage Change From Baseline (Week 0) to Week 1
ClinicalTrials.gov NCT03693430 protocol and results modules
registry, as of 2026-05-18Stale
https://clinicaltrials.gov/study/NCT06041217
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 242. Conditions Overweight; Obesity. This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 y Change in Body Weight (%) Semaglutide 2.4 mg -12.2 Percentage change in body weight Baseline (week 0), end of treatment (week 44) Change in Body Weight (%) Placebo -2.2 Percentage change in body weight Baseline (week 0), end of treatment (week 44) Change in HbA1c (%) Semaglutide 2.4 mg -0.4 Percentage of HbA1c Change in HbA1c (%) Placebo 0.0 Percentage of HbA1c Change in HbA1c (mmol/
ClinicalTrials.gov NCT06041217 protocol and results modules
registry, as of 2026-10-07Stale
https://clinicaltrials.gov/study/NCT05726227
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 212. Conditions Obesity. This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the c
ClinicalTrials.gov NCT05726227 protocol and results modules
registry, as of 2026-01-29Stale
https://clinicaltrials.gov/study/NCT05040971
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 207. Conditions Obesity. This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes. This study will look at how much weight participants lose, and if participants can go from having blood sugar that is higher than normal (prediabetes) to having Change in Body Weight (Percentage [%]) Semaglutide 2.4 mg -14.4 Percentage (%) of body weight From randomisation (week 0) to end of treatment (week 52) Change in Body Weight (Percentage [%]) Placebo -2.7 Percentage (%) of body weight From randomisation (week 0) to end of treatment (week 52) Change in Glycosylated Haemoglobin (HbA1c) Semaglutide 2.4 mg -0.4 Percentage of HbA1c Change in Glycosylated Haemoglobi
ClinicalTrials.gov NCT05040971 protocol and results modules
registry, as of 2025-12-11Stale
https://clinicaltrials.gov/study/NCT04102189
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 201. Conditions Overweight; Obesity. This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents w Percentage of Participants Achieving Greater Than or Equal to (>=) 5% Reduction of Body Weight (Yes/no) Semaglutide 2.4 mg 72.5 Percentage of Participants Achieving Greater Than or Equal to (>=) 5% Reduction of Body Weight (Yes/no) Placebo 17.7 Percentage of Participants Achieving Greater Than or Equal to (>=) 5% Reduction of Body Weight (Yes/no) Semaglutide 2.4 mg 27.5 Percentage of Participants Achieving
ClinicalTrials.gov NCT04102189 protocol and results modules
registry, as of 2025-11-14Stale
https://clinicaltrials.gov/study/NCT06499857
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation. Overall status RECRUITING. Phases PHASE3. Lead sponsor University of Chicago. Enrollment 200. Conditions Overweight or Obesity; Atrial Fibrillation. The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard A
ClinicalTrials.gov NCT06499857 protocol and results modules
registry, as of 2026-09-02Stale
https://clinicaltrials.gov/study/NCT06934655
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth. Overall status RECRUITING. Phases PHASE3. Lead sponsor Children's Hospital Los Angeles. Enrollment 150. Conditions Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide. This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who hav
ClinicalTrials.gov NCT06934655 protocol and results modules
registry, as of 2025-12-30Stale
https://clinicaltrials.gov/study/NCT04998136
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 150. Conditions Obesity. This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get pla Change in Body Weight (%) : In-trial Observation Period Semaglutide -16.4 Percentage of body weight Baseline (week 0), end of treatment (week 44) Change in Body Weight (%) : In-trial Observation Period Placebo -2.6 Percentage of body weight Baseline (week 0), end of treatment (week 44) Change in Body Weight (%) : On-treatment Observation Period Semaglutide -16.4 Percentage of body weight Bas
ClinicalTrials.gov NCT04998136 protocol and results modules
registry, as of 2025-04-22Stale
https://clinicaltrials.gov/study/NCT04889183
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor University Medical Center Groningen. Enrollment 125. Conditions Obesity; Albuminuria. Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide 2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD progression.
ClinicalTrials.gov NCT04889183 protocol and results modules
registry, as of 2025-08-08Stale
https://clinicaltrials.gov/study/NCT06909006
Semaglutide Treatment in Type 1 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Nordsjaellands Hospital. Enrollment 122. Conditions Obesity in Diabetes; Obesity/Therapy; Type 1 Diabetes Mellitus (T1DM); Insulin Sensitivity/Resistance; Semaglutide; Lipidomics; Metabolomics; Weight Loss; Glycemic Control for Diab. The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabete
ClinicalTrials.gov NCT06909006 protocol and results modules
registry, as of 2026-07-02Stale
https://clinicaltrials.gov/study/NCT07021937
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor University of Colorado, Denver. Enrollment 120. Conditions Obesity/Therapy. Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain ci
ClinicalTrials.gov NCT07021937 protocol and results modules
registry, as of 2024-10-15Stale
https://clinicaltrials.gov/study/NCT05087342
Latino Semaglutide Study. Overall status COMPLETED. Phases PHASE3. Lead sponsor Loma Linda University. Enrollment 119. Conditions Obesity; Obesity; Drug; Overweight or Obesity; Weight Loss; Weight Loss Trajectory; Weight, Body. The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
ClinicalTrials.gov NCT05087342 protocol and results modules